2018
Editorial: gastrointestinal safety of COX‐2 selective and nonselective NSAIDs—the impact of the PRECISION trial
Laine L. Editorial: gastrointestinal safety of COX‐2 selective and nonselective NSAIDs—the impact of the PRECISION trial. Alimentary Pharmacology & Therapeutics 2018, 47: 1545-1546. PMID: 29878414, DOI: 10.1111/apt.14642.Commentaries, Editorials and Letters
2004
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial
Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial. Gastroenterology 2004, 127: 395-402. PMID: 15300570, DOI: 10.1053/j.gastro.2004.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalAspirinCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDouble-Blind MethodDrug Therapy, CombinationFemaleGastric MucosaHumansIbuprofenIncidenceIsoenzymesLactonesMaleMembrane ProteinsMiddle AgedOsteoarthritisProstaglandin-Endoperoxide SynthasesRisk FactorsStomach UlcerSulfonesTablets, Enteric-CoatedConceptsNonselective nonsteroidal anti-inflammatory drugsLow-dose aspirinCOX-2 selective inhibitorsDouble-blind trialUlcer incidenceNonselective NSAIDsLow-dose enteric-coated aspirinLow-dose aspirin usersCyclooxygenase-2 selective inhibitorSelective inhibitorNonsteroidal anti-inflammatory drugsEnteric-coated aspirinGastrointestinal mucosal injuryNumber of erosionsRisk of ulcerAnti-inflammatory drugsCOX-2 selective inhibitionYears of ageBaseline endoscopyAspirin usersDose aspirinErosive esophagitisCumulative incidenceMucosal injuryRepeat endoscopyUtilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis
Ofman JJ, Badamgarav E, Henning JM, Knight K, Laine L. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis. The American Journal Of Medicine 2004, 116: 835-842. PMID: 15178499, DOI: 10.1016/j.amjmed.2004.02.028.Peer-Reviewed Original ResearchConceptsCOX-2 inhibitorsCardiac eventsHealth care costsGastrointestinal bleedingTraditional NSAIDsHigh riskGreater total health care costsNonsteroidal anti-inflammatory drug therapyCare costsAnti-inflammatory drug therapyCOX-2 inhibitor therapyTotal health care costsCyclooxygenase-2 selective inhibitorNonsteroidal anti-inflammatory drugsCardiac risk profileProton pump inhibitorsAnti-inflammatory drugsLogistic regression analysisNSAID therapyNSAID usersGastrointestinal riskInhibitor useNonselective NSAIDsInhibitor therapyCardiac risk
2003
Proton pump inhibitor use in patients with indications for low-dose aspirin who start COX-2 selective inhibitors or nonselective NSAIDs
Ofman J, Knight K, Badamgarav E, Henning J, Wallace K, Wong J, Dylan M, Laine L. Proton pump inhibitor use in patients with indications for low-dose aspirin who start COX-2 selective inhibitors or nonselective NSAIDs. Gastroenterology 2003, 124: a107. DOI: 10.1016/s0016-5085(03)80529-2.Peer-Reviewed Original Research
2002
Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis
Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002, 123: 1006-1012. PMID: 12360461, DOI: 10.1053/gast.2002.36013.Peer-Reviewed Original ResearchConceptsUpper GI eventsClinical upper GI eventsSelective cyclooxygenase-2 inhibitorHigh-risk patientsGI eventsRisk factorsCyclooxygenase-2 inhibitorClinical characteristicsRheumatoid arthritisClinical eventsNonsteroidal anti-inflammatory drugsClinical GI eventsRisk of NSAIDUpper GI complicationsLow-risk patientsSevere rheumatoid arthritisPatients' clinical characteristicsRheumatoid arthritis patientsAbsolute risk reductionLow-risk subgroupsAnti-inflammatory drugsIndividual risk factorsRisk of eventsGI complicationsNonselective NSAIDs